• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health to Share Next Chapter of Growth at 2024 Investor Day

    11/20/24 9:00:13 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email

    CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions.

    "The management team is looking forward to the Company's inaugural Investor Day since going public in 2020," said Michael J. Petras, Jr., Chair and CEO. "During the past four years, we have achieved top- and bottom-line growth with strong margins, generated significant operating cash flow, demonstrated disciplined capital deployment, and maintained durable customer relationships. I'm proud of what we've accomplished and look forward to the team sharing more about future growth drivers at today's investor event."

    During today's presentation, management will:

    • Demonstrate the strength and durability of Sotera Health while fulfilling our mission of Safeguarding Global Health®;
    • Provide a detailed perspective of the markets served by the Company and growth opportunities, including our serviceable addressable market of $18 billion;
    • Share customer feedback, which will continue to guide capital investment decisions and the Company's growth outlook;
    • Provide a long-term financial outlook that highlights the focus on Free Cash Flow generation and supports a compelling investment thesis; and
    • Outline our 2025-2027 financial plan to achieve an organic compound annual revenue growth rate of 5% to 7%, expand Adjusted EBITDA margins by at least 50 basis points, drive an organic compound annual Adjusted EBITDA growth rate of 5% to 8%, and generate cumulative Free Cash Flow of more than $500 million.

    The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA, Adjusted EBITDA margins, Adjusted EBITDA growth rate and Free Cash Flow without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.

    Investor Day

    A live webcast of the event will be accessible at Presentation & Events | Sotera Health. Virtual participants are encouraged to pre-register at this link and log in to the webcast approximately 5-10 minutes prior to the start of the event. A live question-and-answer session will follow management's prepared remarks. Sotera Health intends to make the investor presentation for the event available concurrently with the start of the event. A replay of the video webcast will be available within 48 hours following the conclusion of the event at Presentation & Events | Sotera Health. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company's website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.

    INVESTOR RELATIONS CONTACT

    Jason Peterson

    Vice President Investor Relations & Treasurer

    [email protected]

    MEDIA CONTACT

    Kristin Gibbs

    Chief Marketing Officer

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $SHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What event is Sotera Health hosting and what will it entail?

      Sotera Health Company will be holding its inaugural Investor Day in New York City to discuss its strategic positioning and future growth plans.

    • What are the key financial projections shared by Sotera Health's management?

      Management aims for a compound annual revenue growth rate of 5% to 7% from 2025 to 2027, along with other financial objectives including a cumulative Free Cash Flow of over $500 million.

    • Through what business segments does Sotera Health operate?

      Sotera Health operates through three primary segments: Sterigenics, Nordion, and Nelson Labs, providing sterilization solutions and lab testing services.

    • How will the audience participate during the Investor Day event?

      During Investor Day, management will address audience questions through two dedicated Q&A sessions after their presentation.

    • Why can't Sotera Health provide reconcilations for their non-GAAP financial measures?

      Sotera Health has indicated that it cannot provide reconciliations for certain non-GAAP financial measures due to the unpredictability of items impacting net income.

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    12/18/2025Outperform
    William Blair
    11/13/2025$19.00Outperform
    BMO Capital Markets
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    More analyst ratings

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Appoints Kenneth D. Krause to the Board of Directors

    CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company" or "Sotera Health"), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today that it has appointed Kenneth D. Krause as a new independent director to its Board of Directors (the "Board"). Mr. Krause has served as Executive Vice President and Chief Financial Officer of Rollins, Inc. (NYSE:ROL) ("Rollins"), a global consumer and commercial pest control services company, since September 2022. In 2024, his role expanded to include oversight of Rollins' International Brands. During his tenure at

    3/16/26 7:00:00 AM ET
    $ROL
    $SHC
    Diversified Commercial Services
    Consumer Discretionary
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Regist

    3/4/26 4:51:01 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ostrowski Erika

    3 - Sotera Health Co (0001822479) (Issuer)

    4/8/26 4:02:10 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Dimitrief Alexander

    4 - Sotera Health Co (0001822479) (Issuer)

    4/2/26 4:56:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 3 filed by new insider Krause Kenneth D.

    3 - Sotera Health Co (0001822479) (Issuer)

    3/20/26 4:53:14 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital Mkts resumed coverage on Sotera Health with a new price target

    RBC Capital Mkts resumed coverage of Sotera Health with a rating of Outperform and set a new price target of $24.00

    1/9/26 8:12:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    William Blair initiated coverage on Sotera Health

    William Blair initiated coverage of Sotera Health with a rating of Outperform

    12/18/25 9:11:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Sotera Health Company

    DEFA14A - Sotera Health Co (0001822479) (Filer)

    4/8/26 4:33:42 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form DEF 14A filed by Sotera Health Company

    DEF 14A - Sotera Health Co (0001822479) (Filer)

    4/8/26 4:30:52 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    SCHEDULE 13G/A - Sotera Health Co (0001822479) (Subject)

    3/27/26 1:15:44 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date

    CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's websit

    2/17/26 7:30:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results

    Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Comp

    11/4/25 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care